When should intravenous magnesium sulfate be administered for acute severe asthma, what are the recommended adult and pediatric dosages, and what monitoring and contraindications are required?

Magnesium Sulphate in Asthma

For adults with severe acute asthma refractory to initial treatment with bronchodilators and corticosteroids, administer intravenous magnesium sulfate 2 g over 20 minutes; for children, use 50 mg/kg (maximum 2 g) over 20 minutes. This should be considered after 1 hour of intensive conventional therapy has failed to produce adequate improvement.

When to Administer IV Magnesium Sulfate

Adults

Administer IV magnesium sulfate when patients have life-threatening exacerbations or remain severely ill after 1 hour of intensive conventional treatment with oxygen, nebulized beta-agonists, and systemic corticosteroids 1, 2. The 2010 American Heart Association guidelines specifically recommend it for "severe refractory asthma" 2.

Life-threatening features requiring consideration include:

• Peak expiratory flow <33% predicted
• Silent chest, cyanosis, or feeble respiratory effort
• Altered consciousness, exhaustion, or confusion
• PaCO₂ ≥42 mmHg or rising
• Inability to speak 3

Pediatrics

Use IV magnesium sulfate in children with life-threatening features present on arrival or those not improving after 15-30 minutes of initial bronchodilator therapy 4. Life-threatening features in children include:

• PEF <33% predicted or best
• Poor respiratory effort
• Cyanosis, silent chest, fatigue
• Altered level of consciousness
• Respirations >50/min, pulse >140/min 4

Dosing Regimens

Adults

Standard dose: 2 g IV over 20 minutes 2. This represents the most commonly studied and recommended dose based on Cochrane meta-analysis evidence showing improved pulmonary function and reduced hospital admissions 2, 5.

Alternative dosing from older guidelines suggested 1.2-2 g, but the 2 g dose has become standard practice 2.

Pediatrics

Dose: 50 mg/kg (maximum 2 g) IV over 20 minutes 6, 7. Some protocols use:

• Loading dose: 25-75 mg/kg over 20 minutes (maximum 2-2.5 g)
• For severe cases: Consider continuous infusion at 50 mg/kg/hour over 4 hours 8

Target serum magnesium concentration: >4 mg/dL has been suggested as a surrogate marker of efficacy 7, 9.

Administration Details

Dilute to ≤20% concentration before IV administration 10. The rate should generally not exceed 150 mg/minute (1.5 mL of 10% solution per minute) 10.

Common dilution approach:

• Add 2 g magnesium sulfate to 50-100 mL of 5% dextrose or 0.9% sodium chloride
• Infuse over 20 minutes 2, 10

Monitoring Requirements

Essential Monitoring

• Respiratory status: Peak flow, respiratory rate, oxygen saturation every 15-30 minutes initially 3
• Vital signs: Blood pressure (watch for hypotension), heart rate
• Patellar reflexes: Loss indicates magnesium toxicity 10
• Renal function: Especially important as magnesium is renally excreted 3, 10

Laboratory Monitoring

• Serum magnesium levels if continuous infusion used or in renal impairment 10
• Electrolytes (particularly in severe cases) 3
• Arterial blood gases if PaCO₂ concerns or severe distress 1

Contraindications and Precautions

Absolute Contraindications

• Severe renal insufficiency (reduce maximum dose to 20 g/48 hours with frequent monitoring) 10, 6
• Atrioventricular block 6
• Myocardial damage (use with extreme caution) 10

Relative Contraindications and Cautions

• Pregnancy: Continuous administration beyond 5-7 days can cause fetal abnormalities 10
• Hypotension: Monitor closely, though hypotension is uncommon in pediatric studies 9
• Concurrent medications: May reduce antibiotic activity of streptomycin, tetracycline, and tobramycin 10

Expected Adverse Effects

Common but minor side effects include 2:

• Flushing (most common)
• Warmth sensation
• Fatigue
• Nausea
• Headache
• Mild hypotension

These effects are generally well-tolerated and self-limited. Serious adverse events are rare when properly dosed and monitored 6, 5, 9.

Clinical Efficacy Evidence

High-quality evidence demonstrates that IV magnesium sulfate reduces hospital admissions by approximately 7 per 100 adults treated (OR 0.75,95% CI 0.60-0.92) 5. It moderately improves pulmonary function across multiple spirometric indices 2, 5.

For pediatrics, studies show improved respiratory function and reduced hospitalization rates in moderate-to-severe exacerbations refractory to standard therapy 6, 7. A recent pharmacokinetic study identified a target total serum magnesium AUC₀₋₂ₕ >63.1 mg·h/L associated with clinical improvement 9.

Common Pitfalls to Avoid

1. Delaying administration: Magnesium should be given early in severe cases, not as a last resort before intubation 1, 2
2. Inadequate initial therapy: Ensure patients have received appropriate doses of bronchodilators and corticosteroids first 1, 2
3. Ignoring renal function: Always check renal status before administration 10, 6
4. Inappropriate use in mild exacerbations: IV magnesium has no apparent value in lower severity exacerbations 1
5. Forgetting to monitor: Loss of patellar reflexes is an early sign of toxicity requiring immediate cessation 10